Atypical teratoid or rhabdoid tumors: Improved outcome with high-dose chemotherapy

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 5, 2010, Pages e182-e186

  Finkelstein Shechter, Tal ^a   Gassas, Adam ^a   Mabbott, Donald ^a   Huang, Annie ^a   Bartels, Ute ^a   Tabori, Uri ^a   Laura, Janzen ^a   Hawkins, Cynthia ^a   Taylor, Michael ^a   Bouffet, Eric ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Atypical teratoid rhabdoid tumor; High dose chemotherapy; Neurocognitive outcome; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MORPHINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETINOIC ACID; TAMOXIFEN; THIOTEPA; TOPOTECAN; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DRUG MEGADOSE; DYSPNEA; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; INFANT; LEPTOMENINX; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUROSURGERY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOID TUMOR; RHABDOMYOSARCOMA; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; TACHYPNEA; TERATOMA; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME; TUMOR LOCALIZATION; BRAIN TUMOR; METASTASIS; PATHOLOGY; RADIATION DOSE; SKULL IRRADIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD, PRESCHOOL; CISPLATIN; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; HUMANS; INFANT; MALE; NEOPLASM METASTASIS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RHABDOID TUMOR; SURVIVAL RATE; TERATOMA; TREATMENT OUTCOME; VINCRISTINE;

EID: 77955865421     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181dce1a2     Document Type: Article

References (23)

1. Packer RJ, Biegel JA, Blaney S, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol. 2002; 24: 337-342.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica. 2007; 114: 97-109.
3. Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J Clin Oncol. 2005; 23: 7621-7631.
4. Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg. 1996; 85: 56-65.
5. Hilden JM, Meerbaum S, Burger P, et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol. 2004; 22: 2877-2884.
6. Burger PC, Yu IT, Tihan T, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Amer J Surgical Pathol. 1998; 22: 1083-1092.
7. Tekautz TM, Fuller CE, Blaney S, et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005; 23: 1491-1499.
8. Ho DM, Hsu CY, Wong TT, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a comparative study with primitive neuroectodermal tumor/medulloblastoma. Acta Neuropathologica. 2000; 99: 482-488.
9. Hilden JM, Watterson J, Longee DC, et al. Central nervous system atypical teratoid tumor/rhabdoid tumor: response to intensive therapy and review of the literature. J Neurooncol. 1998; 40: 265-275.
10. Gardner SL, Asgharzadeh S, Green A, et al. Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors. Pediatr Blood Cancer. 2008; 51: 235-240.
11. Hilden JM BJ, Rorke L, et al. Registry for central nervous system (CNS) atypical teratoid tumor/rhabdoid tumor (AT/RT): Treatment and outcome in 18 cases. 2000 June 11-14, 2000; San Francisco.
12. Perry A, Fuller CE, Judkins AR, et al. INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. Mod Pathol. 2005; 18: 951-958.
13. Olson TA, Bayar E, Kosnik E, et al. Successful treatment of disseminated central nervous system malignant rhabdoid tumor. J Pediatr Hematol Oncol. 1995; 17: 71-75.
14. http://www.cancer.gov/clinicaltrials/COG-99703. Accessed January 3, 2010.
15. Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009; 27: 385-389.
16. Arndt CA, Krailo MD, Steinherz L, et al. A Phase II clinical trial of idarubicin administered to children with relapsed brain tumors. Cancer. 1998; 83: 813-816.
17. Ronghe MD, Moss TH, Lowis SP. Treatment of CNS malignant rhabdoid tumors. Pediatr Blood Cancer. 2004; 42: 254-260.
18. Marina NM, Cochrane D, Harney E, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res. 2002; 8: 413-418.
19. Koukourakis MI, Koukouraki S, Fezoulidis I, et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. British J Cancer. 2000; 83: 1281-1286.
20. Chen YW, Wong TT, Ho DM, et al. Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience). Int J Radiat Oncol Biol Phys. 2006; 64: 1038-1043.
21. Radcliffe J, Bunin GR, Sutton LN, et al. Cognitive deficits in long-term survivors of childhood medulloblastoma and other noncortical tumors: age-dependent effects of whole brain radiation. Int J Dev Neurosci. 1994; 12: 327-334.
22. January 3, 2010. http://www.cancer.gov/clinicaltrials/COG-ACNS0333. Accessed January 3, 2010.
23. Alarcon-Vargas D, Zhang Z, Agarwal B, et al. Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors. Oncogene. 2006; 25: 722-734.